These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 26910730)

  • 1. Drug Resistance to EGFR Inhibitors in Lung Cancer.
    Tetsu O; Hangauer MJ; Phuchareon J; Eisele DW; McCormick F
    Chemotherapy; 2016; 61(5):223-35. PubMed ID: 26910730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
    Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
    Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming resistance in non-small-cell lung cancer: A practical lesson for the medicinal chemist.
    Ribaudo G; Zanforlin E; Zagotto G
    Arch Pharm (Weinheim); 2018 Oct; 351(10):e1800037. PubMed ID: 30101528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.
    Iwama E; Nakanishi Y; Okamoto I
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):267-276. PubMed ID: 29363369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives.
    Zükin M
    Rev Assoc Med Bras (1992); 2012; 58(2):263-8. PubMed ID: 22569624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.
    Morgillo F; Amendola G; Della Corte CM; Giacomelli C; Botta L; Di Maro S; Messere A; Ciaramella V; Taliani S; Marinelli L; Trincavelli ML; Martini C; Novellino E; Ciardiello F; Cosconati S
    J Med Chem; 2017 Sep; 60(17):7447-7458. PubMed ID: 28787156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI].
    Shao Y; Zhong D
    Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):381-387. PubMed ID: 32429639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
    Takeda M; Okamoto I; Fujita Y; Arao T; Ito H; Fukuoka M; Nishio K; Nakagawa K
    J Thorac Oncol; 2010 Mar; 5(3):399-400. PubMed ID: 20186026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].
    Moldvay J; Peták I
    Magy Onkol; 2012 Mar; 56(1):38-49. PubMed ID: 22403761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
    Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L
    Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
    Jin J; Liu BZ; Wu ZM
    J Cancer Res Ther; 2015 Nov; 11 Suppl():C271-4. PubMed ID: 26612451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
    Daga A; Ansari A; Patel S; Mirza S; Rawal R; Umrania V
    Asian Pac J Cancer Prev; 2015; 16(10):4147-56. PubMed ID: 26028064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
    Engle JA; Kolesar JM
    Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.
    Nie W; Tao X; Wei H; Chen WS; Li B
    Oncotarget; 2015 Sep; 6(28):25696-700. PubMed ID: 26325082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies.
    Carrera S; Buque A; Azkona E; Aresti U; Calvo B; Sancho A; Arruti M; Nuño M; Rubio I; de Lobera AR; Lopez C; Vivanco GL
    Clin Transl Oncol; 2014 Apr; 16(4):339-50. PubMed ID: 24307395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
    Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.